Publications, posters et comptes rendus

Le personnel du MVP et les partenaires du projet publient des articles scientifiques et participent régulièrement à des conférences nationales et internationales sur la méningite, l’épidémiologie et le développement de vaccins. Certaines des publications et certains des posters et comptes rendus qui ne sont pas repris dans la section Recherche et développement sont mentionnés ci-dessous.

D'autres publications sur la méningite à méningocoques, les vaccins antiméningococciques, l’épidémiologie et la recherche vaccinale sont également accessibles dans la bibliothèque de PATH.

Publications

Beresniak A, Bertherat E, Perea W, et al. A Bayesian network approach to the study of historical epidemiological databases: modelling meningitis outbreaks in the Niger. Bulletin of the World Health Organization. 2012;1(90):412–417.

Brooke S, Harner-Jay CM, Lasher H, Jacoby E. How public-private partnerships handle intellectual property: the PATH experience. In Krattiger A, Mahoney RT, Nelsen L, et al, eds. Intellectual Property Management in Health and Agricultural Innovation: A Handbook. Oxford, UK: MIHR; 2007:1755–1763. (pdf 261 kb).

Caugant DA, Kristiansen PA, Wang X, et al. Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS One. 2012;7(9):e46019.

Chaibou M, Bako H, Salisou L, et al. Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010. Vaccine. 2012;30(35):5229–5234. Voir le compte-rendu (en anglais).

Colombini A, Badolo O, Gessner B, Jaillard P, Seini E, Da Silva A. Costs and impact of meningitis epidemics for the public health system in Burkina Faso. Vaccine. 2011;29(33):5474–5480. Voir le compte-rendu (en anglais).

Colombini A, Bationo F, Zongo S, et al. Costs for households and community perception of meningitis epidemics in Burkina Faso. Clinical Infectious Diseases. 2009;49(10):1520–1525. Voir le compte rendu (en anglais).

Djingarey M, Barry R, Bonkoungou M, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience. Vaccine. 2012 Suppl 2:B40–45. Voir le compte-rendu (en anglais)..

Djingarey M, Kandolo D, Lingani C, et al. Evaluation of meningitis surveillance before introduction of serogroup A meningococcal conjugate vaccine — Burkina Faso and Mali. Morbidity and Mortality Weekly Report. 2012;61(50):1025–1028.

Findlow H, Plikaytis B, Aase A, et al. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults. Clinical and Vaccine Immunology. 2009;16(7):969–977. Voir le compte rendu (en anglais).

Findlow H, Sow S, Borrow R, et al. Meningococcal group C and w135 immunological hyporesponsiveness in African toddlers. Clinical and Vaccine Immunology. 2011;18(9):1492–1496. Voir le compte rendu (en anglais).

Foschiatti M, Hearshaw M, Cescutti P, Ravenscroft N, Rizzo R. Conformational studies of the capsular polysaccharide produced by Neisseria meningitidis group A. Carbohydrate Research. 2009;344(7):940–943. Voir le compte rendu (en anglais).

Frasch C, Preziosi MP, LaForce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac (TM). Human vaccines & immunotherapeutics. 2012;8(6):715–724. Voir le compte-rendu (en anglais).

Harrison LH, Pelton SI, Wilder-Smith A, et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine. 2011;29(18):3363–3371. Voir le compte rendu (en anglais).

Hirve S, Bavdekar A, Pandit A, et al. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial. Vaccine. 2012;30(45):6456–6460. Voir le compte-rendu (en anglais).

Jodar L, Feavers I, Salisbury D, Granoff D. Development of vaccines against meningococcal disease. Lancet. 2002;359(9316):1499–1508. Voir le compte rendu (en anglais).

Kieny M-P, LaForce M. The promise of conjugate vaccines for Africa. Vaccine. 2007;3(25) Suppl 1:A108–110. Voir le compte rendu (en anglais).

Kim SH, Pezzoli L, Yacouba H, et al. Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010. PLoS one . 2012;7(1):1–6.

Kristiansen PA, Diomandé F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clinical Infectious Diseases. 2013;56(3)354–363. Voir le compte-rendu (en anglais).

Kristiansen PA, Diomandé F, Ouédraogo R, et al. Carriage of Neisseria lactamica in 1- to 29-year-old people in Burkina Faso: epidemiology and molecular characterization. Journal of Clinical Microbiology. 2012;50(12):4020–4027. Voir le compte-rendu (en anglais).

Kristiansen PA, Ouédraogo AS, Sanou I, et al. Laboratory quality control in a multicentre meningococcal carriage study in Burkina Faso. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2012;106(5);289–297. Voir le compte-rendu (en anglais).

Kshirsagar N, Mur N, Thatte U, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine. 2007; 3(25) Suppl 1:A101–107. Voir le compte rendu (en anglais).

LaForce M, Konde K, Viviani S, Préziosi M-P. The Meningitis Vaccine Project. Vaccine. 2007;3(25) Suppl 1:A97–100. Voir le compte rendu (en anglais).

LaForce FM, Okwo-Bele JM. Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Affairs. 2011;30(6):1049–1057. Voir le compte rendu (en anglais).

LaForce M, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to group A Neisseria meningitidis in the African meningitis belt: A persistent problem with an imminent solution. Vaccine. 2009;24(27) Suppl 2:B13–19. Voir le compte rendu (en anglais).

Lee C, Kuo W, Beri S, et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine. 2009; 27(5):726–32. Voir le compte rendu (en anglais).

Marchetti E, Mazarin-Diop V, Chaumont J, et al. Conducting vaccine clinical trials in sub-Saharan Africa: operational challenges and lessons learned from the Meningitis Vaccine Project. Vaccine. 2012;30(48):6859–6863. Voir le compte-rendu (en anglais).

Médah I, Yélbeogo D, Kambou JL, et al. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign — Burkina Faso, 2011. Morbidity and Mortality Weekly Report. 2012;61(50):1022–1024.

Novak R, Kambou JL, Diomandé F, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. The Lancet Infectious Diseases. 2012;12(10):757–764.

Ouandaogo C, Yameogo T, Diomandé F, et al. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010. Vaccine. 2012;30 Suppl 2:B46–B51. Voir le compte-rendu (en anglais).

Organisation mondiale de la Santé (OMS). Procédures opérationnelles standard pour la surveillance renforcée de la méningite en Afrique. 2009. (pdf 255 kb).

Organisation mondiale de la Santé (OMS). Recommendations to assure the quality, safety and efficacy of group A meningococcal conjugate vaccines. 2006;BS/06.2041. (en anglais). (pdf 442 kb).

Organisation mondiale de la Santé (OMS). Surveillance renforcée de la méningite à méningocoques en Afrique: trois années d'expérience. Relevé épidémiologique hebdomadaire. 2005;37(80):313–320. (pdf 537 kb).

Organisation mondiale de la Santé (OMS). Méningococcie dans les pays de la ceinture africaine de la méningite (2012) - Nouveaux besoins et perspectives. Relevé épidémiologique hebdomadaire. 2013;12(88):129-136. (pdf 1,1 mb).

Soriano-Gabarro M, Rosenstein N, LaForce FM. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project. Journal of Health, Population, and Nutrition. 2004;22(3):275–285. Voir le compte rendu (en anglais).

Sow S, Okoko B, Diallo A, et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. New England Journal of Medicine. 2011; 364:2293–2304.

Tall H, Hugonnet S, Donnen P, et al. Definition and characterization of localised meningitis epidemics in Burkina Faso: a longitudinal retrospective study. BMC Infectious Diseases. 2012;12(2).

Thomson M, Molesworth A, Djingarey M, Yameogo K, Belanger F, Cuevas L. Potential of environmental models to predict meningitis epidemics in Africa. Tropical medicine & international health. 2006;11(6):781–788. Voir le compte rendu (en anglais).

Posters

Badolo O, Tiendrebeogo E, Novak R, et al. Surveillance of meningococcal disease in Burkina Faso. Poster presented at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. P234 (pdf 4.21 mb).

Caugant D, Tamboura B, Tapia M, et al. Lessons from meningococcal carriage studies in West Africa. Poster presented at: 10th European Monitoring Group for Meningococci meeting, 17–19 June 2009; Manchester, United Kingdom. (pdf 131 kb).

Caugant D, Tamboura B, Tapia M, et al. Carriage of Neisseria meningitidis in 2–29 years old in Mali, Senegal, and The Gambia. Poster presented at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. P168 (pdf 4.21 mb).

Colombini A, Badolo O, Jaillard P, et al. Socioeconomic study of meningitis epidemic impact in Burkina Faso. 2011 (pdf 124 kb).

Djingarey M,  Noazin S, Préziosi MP, et al. A 20-year retrospective analysis of epidemic meningitis surveillance data in Burkina Faso, Mali, and Niger. Poster presented at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. P166 (pdf 669 kb).

Djingarey M, Perea W, Bertherat E, et al. Implementation of standard operating procedures for enhanced meningitis surveillance in 13 countries of the African meningitis belt from 2003 to 2008. Poster presented at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. P231 (pdf 4.21 mb).

Findlow H, Borrow R, Sow S, et al. Meningococcal serogroup C and W135 immunological hyporesponsiveness in African toddlers. Poster presented at: 10th European Monitoring Group for Meningococci meeting, 17–19 June 2009; Manchester, United Kingdom. (pdf 4.02 mb).

LaForce M. Nearing success: The development of an affordable group A meningococcal conjugate vaccine to eliminate epidemic meningitis from Africa. Oral presentation at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. O62 (pdf 4.21 mb).

Préziosi M-P, Hodgson A, Findlow F, et al. A Meningococcal A conjugate vaccine trial in infancy: a step towards routine immunization in the African meningitis belt. Poster presented at: 18th International Pathogenic Neisseria Conference, 9-14 September 2012, Würzburg, Germany. P185 (pdf 1.40 mb).

Ravenscroft N, Hearshaw M, Martino A, et al. Physicochemical and immunological characterization of the drug product (final lot) of a meningococcal group A conjugate vaccine. Poster presented at: 16th International Pathogenic Neisseria Conference, 7–12 September 2008; Rotterdam, the Netherlands. P101 (pdf 4.21 mb).

Documents du MVP

LaForce M. Introduction of a group A meningococcal conjugate
vaccine in sub-Saharan Africa: Cost/savings analysis. MVP unpublished data. 2008. (pdf 623 kb).